FISH (Fluorescent in Situ Hybridization) Probe Market (By Technology: Q FISH, Flow FISH, Other FISH; By Type: RNA [mRNA, miRNA, Other], DNA; By Application: Genetic Diseases, Cancer Research [Breast, Lung, Gastric, Prostrate, Bladder, Hematological, Cervical, Other], Other; By End Use: Clinical, Research, Companion diagnostics) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026

Category : ICT | Delivery Format : PDF | Status: Published | Pages : 190

Introduction

According to Acumen Research and Consulting, the global FISH Probe market is expected to grow at noteworthy CAGR around 6.5 % throughout the forecast period and reach around US$ 1 billion by 2026.

Fluorescent in situ hybridization (FISH) is a method used by molecular cytogenetic devices to visualize and map the genetic components of an individual. The method is used to distinguish fluorescent samples attached to the chromosome with a fluorescent microscope. FISH method has broad applications in the diagnostic sector such as structural and numerical chromosome defects, marker chromosome characterisation, drug tracking and identification of unusual and genetic conditions. The method also applies in clinical studies, including gene mapping and somatic cell hybrid characterization. Three separate FISH samples, each with distinct apps, are commercially accessible.

The report provides analysis of global FISH Probe market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year.

Market Dynamics

Increasing demand is anticipated to drive demand in future years for IVD diagnostic tools for different chronic diseases. The elevated degree of reliability, speed and awareness of the technology of the FISH probe which is to propagate the FISH market is ascribed to the increasing demand for IVD. In medical diagnostics, DNA sample-based diagnosis is gaining in popularity to determine suspected illnesses induced by pathogen or bacteria. Moreover, identifying the new diagnostic market regions, increasing diagnostic test automation and investments in pharmaceutical research and pharmaceutical research are the main drivers of development. Increased incidence of genetic disorders like Acute Lymphoblastic Leukemia (ALL) drives market development further. In 2018, nearly 7,000 fresh instances of ALL, with over 1500 fatalities, were diagnosed in Instance, according to the American Cancer Society.

The increased incidence of cytogenic-based illnesses, such as genetic abnormalities and cancer, in conjunction with demand for fast, sensitive and precise disease validation prediction methods is expected to increase FISH testing methods and thus increase the development of markets over the projected period.

The growth in the Fluorescent In Situ Hybridisation (FISH) test industry is also attributable to the growing R&D projects undertaken by different main players in the creation of new biomarkers and pipeline products for disease specific waiting for regulatory authorization. The market will be further driven by increased awareness, increased healthcare costs and the creation of new samples.

Type Outlook

Due to increasing demand for molecular profiling by healthcare practitioners, mRNA segment retained the biggest income market share in 2018. The increasing demand is further supported by technologically sophisticated molecular pathological instruments which assist in disease prognosis and stratification for adequate therapy.

Most of the RNA samples are used to analyze the cancer and help differentiate between subtypes of cancer. Companies such as the Advanced Cell Diagnostics series on Cancer and Infectious Diseases RNAscope and the Stellaris RNA BioSearch Technologies are developing new samples aiming at disease-specific RNA. Include INFORM HER 2/NEU sample from Ventana Medical Systems, PATHYVISION HER-2 from Abbott Molecular and HER2 FISH PharmDx from Dako Danmark, which have been recently approved as fluorescent hybridization kits for accompanying diagnostic use.

Market players provide custom-made, precise test development services in accordance with customer requirements. The expensive nature of the reagent, hard RNA tagging procedures and more complex procedures are expensive due to the synthesis of the RNA probes. RNA samples are more preferable since RNA-RNA hybrids are known to be stably more than DNA-RNA hybrids that increase the efficiency of the labeling response. Roche Molecular's Ventana ALK CDx testing by Ventana Medical systems and RG7422 PI3 K Inh waiting for permission and anticipated to be marketed during the projected timeframe.

Application Outlook

The hybridizing fluorescent-in-situ probe is most often used in genetic and cancer studies. Increasing cancer incidence worldwide and demand for delicate, quick and precise molecular diagnostic exams will drive general market development in the coming years. FISH samples are commonly used to detect breast and lung cancer in cancer diagnostics.

Genetic diseases segments are anticipated to enjoy quicker demand than cancer and other segments, depending on the present rate of execution and future opportunities of development. In the present situation, for example, FISH samples ' market penetration is highest in cancer diagnostics and consequently the segment has accounted for a greater market share.

On the other side, for other medical apps, the penetration of these samples is relatively less, accounting therefore for a relatively lower market share. Increased R&D in genetic and other infectious disease screening is, however, projected to be a profitable platform in the near future. With genetic diseases, the market penetration is currently lower, but the R&D activity in chromosomal aberrations is anticipated to increase at a substantial pace.

End Use Stance

The most significant method to detect genetic abnormalities is fluorescence in situ hybridisation. They are frequently used in clinical, complementary and research studies. Due to the broad applications in the identification of genetic disorders, cancer and infectious illnesses, clinical segments were the biggest markets share in 2018.

The specificity and elevated sensitivity of this technology and the fast performance tests have turned it into an important cytogenetic test that provides significant results for hematological malignancies and solid tumors research and diagnostic studies.

These samples are used in gene mapping and genetic aberrations study studies and the identification of new oncogenes in the detection and therapy of cancer. It is also used for gene mapping and identification in molecular screening of novel oncogenes. Extensive genetic abbreviation studies are being ascribed to the growth segment, with illnesses and the increased incidence of genomic abnormalities and cancer.

Regional Stance

High incidence of genetic disorders resulting in birth defects, developmental disabilities and other metabolisms are among those attributed to development. North America has been ascribed the highest share of revenues in 2018. In 2017, around 3% to 4% of newborns in the United States were born with genetic defects, the Center for Disease Control and Prevention (CDC). Roughly 10% of adults and 30% of kids were hospitalized in the nation due to genetic illnesses. Fluorescent ISH is estimated to be 98% accurate to detect chromosomal aberrations that cause these disturbances.

The use of this test is also increasing in this region and will drive demand for multiple illnesses, such as cancer and genetic disorders. The market development is mainly ascribed to increased knowledge among individuals of genetic disease early diagnosis, increased availability incomes and extremely well-established R&D facilities. Favorable healthcare reimbursement policies and government reforms are anticipated to push the industry further.

In the coming years, Asia Pacific is expected to show profitable development. In this area, the sector is increasing in terms of the generation of income from cytogenetics and molecular diagnostics. The variables that encourage regional development are the presence of government supporting measures for growing producers ' and public investments in biotechnology and elevated untapped possibilities.

Continuous R&D for cancer therapy also makes demand for cancer studies easier and should in the near future fuel regional demand. The growing use of fresh molecular cytogenetic methods, increasing outsourcing operations and demand for early diagnosis and disease detection are expected to boost regional development. regional growth is expected.

Market Segmentation

Global FISH Probe Market, By Technology

  • Q FISH
  • Flow FISH
  • Other FISH

Global FISH Probe Market, By Type

  • RNA
    • mRNA
    • miRNA
    • Other
  • DNA

Global FISH Probe Market, By Application

  • Genetic Diseases
  • Cancer Research
    • Breast
    • Lung
    • Gastric
    • Prostrate
    • Bladder
    • Hematological
    • Cervical
    • Other
  • Other

Global FISH Probe Market, By End Use

  • Clinical
  • Research
  • Companion diagnostics

Global FISH Probe Market, By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa (MEA)

The market research study on “FISH (Fluorescent in Situ Hybridization) Probe Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers detailed insights on global FISH Probe market segments with market dynamics and their impact. The report also covers basic technology development policies.

Key Players & Strategies

Life Science Technologies; Oxford Gene Technologies; Genemed Biotechnologies, Abnova Corporation; Inc. PerkinElmer Inc.; Biosearch Technologies Inc.; and F. Hoffmann-La Roche AG are main players running on the market. Some businesses including Abbott Laboratories and Agilent Technologies have large market shares because of the comprehensive product portfolio such as Vysis EGR1 FISH Probe Kit by Abbott are competitive by nature on the market.

Companies use competitive approaches to gain benefit, such as fresh product development, strategic partnerships and regional expansions. Oxford Gene Technology, for example, has extended its Cytocell Aquarius FISH range of pathology samples in 2016. In 2016, the firm also launched a fresh line of in situ hybridizing non-human fluorescent samples for pig, mouse and chicken.


Frequently Asked Questions

Cart Summary